Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Non Operating Income (2023 - 2025)

Historic Non Operating Income for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$1.4 million.

  • Inhibrx Biosciences' Non Operating Income fell 14923.29% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 10005.24%. This contributed to the annual value of $2.0 billion for FY2024, which is 994744.67% up from last year.
  • Inhibrx Biosciences' Non Operating Income amounted to -$1.4 million in Q3 2025, which was down 14923.29% from -$1.3 million recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Non Operating Income registered a high of $2.0 billion during Q2 2024, and its lowest value of -$6.0 million during Q3 2023.
  • Its 3-year average for Non Operating Income is $200.1 million, with a median of -$1.4 million in 2025.
  • Per our database at Business Quant, Inhibrx Biosciences' Non Operating Income skyrocketed by 3546984.93% in 2024 and then crashed by 14923.29% in 2025.
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Non Operating Income stood at -$3.7 million in 2023, then soared by 155.98% to $2.1 million in 2024, then tumbled by 170.0% to -$1.4 million in 2025.
  • Its Non Operating Income stands at -$1.4 million for Q3 2025, versus -$1.3 million for Q2 2025 and -$410000.0 for Q1 2025.